Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Dechra Pharmaceuticals PLC Director's Dealing 2018

Feb 27, 2018

4797_dirs_2018-02-27_e8d4ef23-5b8a-4753-9fc7-a39a7bdc6952.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1173G

Dechra Pharmaceuticals PLC

27 February 2018

27 February 2018

Dechra Pharmaceuticals PLC

(the Company)

Director Shareholding

Dechra Pharmaceuticals PLC has been notified that on 26 February 2018 Lawson Macartney, Non-Executive Director, purchased 2,940 American Depositary Receipts (ADRs) in the Company at a price of US$68 each. This is equivalent to 5,880 ordinary shares in the Company.

Following this acquisition, Lawson Macartney's beneficial interest in the Company is 5,880 shares (0.006% of the current issued share capital).

The Notification of Dealing Form set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Form

1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a) Name Lawson Macartney
2. Reason for the notification
a) Position/status Director
b) Initial notification/

amendment
Initial Notification
3. Details of the Issuer
a) Name Dechra Pharmaceuticals PLC
b) LEI code 213800J4UVB5OWG8VX82
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument

Identification code
American Depositary Receipts (ADRs) in Dechra Pharmaceuticals PLC (each ADR represents 2 ordinary shares

DPHAY/CUSIP: 243435-10-4
b) Nature of the transaction Purchase of ADRs
c) Price(s) and volumes(s) Price(s)

$68
2,940
d) Aggregated information

-   Aggregate volume

-   Price

-   Total
2,940

$68

$199,920
e) Date of the transaction 2018-02-27
f) Place of the transaction United States

For further information, please contact:

Melanie Hall, Company Secretary             

Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHFKODDQBKDPBB